Previous reports have revealed that genetic alterations, such as BRAF mutations, TERT mutations, and RET/PTC rearrangement, can promote tumor proliferation and metastasis, which result in poor PTC prognosis; these actions are mediated through the Mitogen-Activated Protein Kinase (MAPK/ERK) and Phosphoinositide 3-kinase (PI3K)/Protein kinase B (AKT) pathways3. The gene discussed is RET; the disease is neoplasm.